Microbot Medical details $39,230,691 ATM program
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C.
Rhea-AI Filing Summary
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C. Wainwright & Co. Under this arrangement, the company may sell shares of its common stock, par value $0.01 per share, from time to time up to an aggregate offering price of $39,230,691.
Sales can occur on the Nasdaq Capital Market, through market makers, or directly to Wainwright in negotiated transactions at prevailing market prices or prices related to them. These sales will be made under a shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement filed with the SEC. The company also filed a legal opinion from its counsel on the validity of the shares.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM Program Aggregate Offering Price: $39,230,691
Common Stock Par Value: $0.01 per share
Trading Symbol: MBOT
3 metrics
ATM Program Aggregate Offering Price
$39,230,691
Maximum aggregate offering price of ATM Shares under the program
Common Stock Par Value
$0.01 per share
Par value of Microbot Medical common stock eligible for ATM Sales
Trading Symbol
MBOT
Common stock listed on Nasdaq Capital Market
Key Terms
at the market offering, shelf registration statement on Form S-3, prospectus supplement, at the market offering program, +1 more
5 terms
at the market offering financial
"in connection with the Company’s “at the market offering” program (the “ATM Program”)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
shelf registration statement on Form S-3 regulatory
"prospectus supplement to the Company’s shelf registration statement on Form S-3 (File No. 333-275634)"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
prospectus supplement regulatory
"The Company will file a prospectus supplement to the Company’s shelf registration statement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
at the market offering program financial
"in connection with the Company’s “at the market offering” program (the “ATM Program”)"
An at-the-market offering program is a method a publicly traded company uses to sell newly issued shares directly into the open market at current market prices, usually through a broker. It lets the company raise capital gradually and flexibly — think of selling small amounts at the going price rather than holding a single big auction — which can dilute existing shareholders and affect share supply and price depending on how much and how often shares are issued.
emerging growth company regulatory
"Emerging Growth Company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What is Microbot Medical (MBOT) announcing in this 8-K filing?
Microbot Medical is highlighting its ability to sell common stock under an at-the-market program with H.C. Wainwright. The company may offer shares up to an aggregate price of $39,230,691 under an existing Form S-3 shelf registration and a related prospectus supplement.
How large is Microbot Medical’s at-the-market offering program?
The at-the-market program permits Microbot Medical to sell common stock with an aggregate offering price of up to $39,230,691. These shares may be issued over time under a shelf registration statement on Form S-3 using a prospectus and related prospectus supplement filed with the SEC.
What securities are covered by Microbot Medical’s ATM program?
The program covers shares of Microbot Medical’s common stock, par value $0.01 per share, referred to as ATM Shares. These shares may be sold from time to time up to a total aggregate offering price of $39,230,691 under the company’s Form S-3 shelf registration statement.
Who acts as sales agent for Microbot Medical’s at-the-market offering?
H.C. Wainwright & Co., LLC acts as sales agent under the At the Market Offering Agreement. It may execute sales of Microbot Medical’s common stock on Nasdaq, through market makers, or directly as principal in negotiated transactions at market prices or prices related to them.
AI-generated analysis. How Rhea-AI works. Not financial advice.
